Rep. Gilbert Ray Cisneros, Jr. Purchases NeoGenomics, Inc. (NASDAQ:NEO) Stock

Key Points

• Rep. Gilbert Ray Cisneros, Jr. purchased between $1,001 and $15,000 in NeoGenomics, Inc. stock on May 7th, reflecting his personal investment strategy through his "150 MAIN STREET TRUST" account.
• NeoGenomics shares recently fell 2.9% to $6.42, with a market cap of $826.25 million and mixed financial performance outlined in their latest earnings.
• Several large investors have increased their stakes in NeoGenomics, indicating a growing institutional interest in the company despite its current stock valuation challenges.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of NeoGenomics, Inc. (NASDAQ:NEO). In a filing disclosed on June 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in NeoGenomics stock on May 7th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of SpringWorks Therapeutics NASDAQ: SWTX on 7/1/2025.
• Purchased $1,001 - $15,000 in shares of AppLovin NASDAQ: APP on 7/1/2025.
• Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 6/30/2025.
• Purchased $1,001 - $15,000 in shares of CoStar Group NASDAQ: CSGP on 6/30/2025.
• Purchased $15,001 - $50,000 in shares of CoStar Group NASDAQ: CSGP on 6/27/2025.
• Purchased $1,001 - $15,000 in shares of Xiaomi OTCMKTS: XIACF on 6/27/2025.
• Sold $1,001 - $15,000 in shares of ASML NASDAQ: ASML on 6/27/2025.
• Sold $1,001 - $15,000 in shares of Willis Towers Watson Public NASDAQ: WTW on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Boston Scientific NYSE: BSX on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Liberty Media Corporation - Liberty Formula One Series C NASDAQ: FWONK on 6/26/2025.

NeoGenomics Trading Down 2.9%

Shares of NEO opened at $6.42 on Friday. The firm's fifty day moving average is $7.25 and its two-hundred day moving average is $9.75. The stock has a market cap of $826.25 million, a PE ratio of -10.52 and a beta of 1.63. The company has a quick ratio of 1.95, a current ratio of 2.05 and a debt-to-equity ratio of 0.38. NeoGenomics, Inc. has a 52-week low of $6.08 and a 52-week high of $19.11.

NeoGenomics (NASDAQ:NEO - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The medical research company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.06). NeoGenomics had a negative return on equity of 2.21% and a negative net margin of 11.54%. The business had revenue of $168.04 million for the quarter, compared to analyst estimates of $171.38 million. During the same quarter in the previous year, the firm posted ($0.02) earnings per share. The business's revenue was up 7.6% compared to the same quarter last year. Research analysts forecast that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On NeoGenomics

Several large investors have recently made changes to their positions in the stock. Blue Trust Inc. lifted its stake in NeoGenomics by 33.2% during the 4th quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company's stock worth $73,000 after acquiring an additional 1,103 shares in the last quarter. KBC Group NV lifted its position in shares of NeoGenomics by 44.7% during the fourth quarter. KBC Group NV now owns 6,557 shares of the medical research company's stock worth $108,000 after purchasing an additional 2,027 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of NeoGenomics by 18.7% in the fourth quarter. Jennison Associates LLC now owns 1,514,756 shares of the medical research company's stock valued at $24,963,000 after purchasing an additional 238,288 shares during the period. Strategic Financial Concepts LLC purchased a new position in shares of NeoGenomics in the fourth quarter valued at approximately $220,000. Finally, Rhumbline Advisers grew its holdings in shares of NeoGenomics by 2.4% in the fourth quarter. Rhumbline Advisers now owns 389,003 shares of the medical research company's stock valued at $6,411,000 after purchasing an additional 9,098 shares in the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Anthony P. Zook acquired 18,900 shares of the firm's stock in a transaction dated Tuesday, May 6th. The stock was acquired at an average price of $7.88 per share, for a total transaction of $148,932.00. Following the purchase, the chief executive officer owned 18,900 shares of the company's stock, valued at $148,932. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Michael Aaron Kelly purchased 5,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 27th. The stock was purchased at an average price of $7.60 per share, with a total value of $38,000.00. Following the purchase, the director directly owned 5,000 shares of the company's stock, valued at $38,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 70,600 shares of company stock worth $550,438 over the last 90 days. Company insiders own 2.40% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on NEO shares. Wall Street Zen raised NeoGenomics from a "sell" rating to a "hold" rating in a research note on Tuesday, May 13th. Leerink Partners cut shares of NeoGenomics from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $25.00 to $9.00 in a research report on Wednesday, April 30th. Morgan Stanley dropped their price objective on shares of NeoGenomics from $17.00 to $10.00 and set an "equal weight" rating for the company in a report on Thursday, May 1st. Leerink Partnrs downgraded shares of NeoGenomics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Finally, Guggenheim initiated coverage on shares of NeoGenomics in a report on Thursday, May 15th. They issued a "neutral" rating on the stock. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, NeoGenomics currently has an average rating of "Hold" and an average target price of $13.83.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.